The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

8114158064808047588f31fd07-f2ab-4fbc-a61f-4ceb845956f8df73e933-0850-4d45-b115-ad2c4ba43be5fd539e46-a93e-4135-8451-389b13848f49ARGS_News_2015_2_24_General_Releases.pdfARGS_News_2015_2_2_General_Releases.pdfARGS_News_2015_1_23_General_Releases.pdf1705214324175241232015-2-24T8:30:0-5:02015-2-2T16:30:0-5:02015-1-23T11:0:0-5:0897956894187892671General ReleasesGeneral ReleasesGeneral ReleasesDr. Fred Miesowicz Will Present a Case Study Review of Logistics of Cell Therapy Manufacturing on January 26th and Will Participate in a Breakfast Briefing on January 27thJoan C. Winterbottom Joins Argos Therapeutics as Chief Human Resources OfficerArgos Therapeutics to Present at the 17th Annual BIO CEO & Investor ConferenceArgos Therapeutics Chief Operating Officer to Speak at Phacilitate Cell & Gene Therapy Forum 2015838383201520152015No Error0

Joan C. Winterbottom Joins Argos Therapeutics as Chief Human Resources Officer
Read more

Argos Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
Read more

Argos Therapeutics Chief Operating Officer to Speak at Phacilitate Cell & Gene Therapy Forum 2015
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC